| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | M T Andersen | |
| M K Andersen | |||
| D H Christiansen | |||
| J Pedersen-Bjergaard | |||
| P2860 | cites work | CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations | Q27824809 |
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype | Q27824827 | ||
| RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years | Q27824840 | ||
| Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations | Q27824843 | ||
| Implications of NRAS mutations in AML: a study of 2502 patients | Q27824859 | ||
| Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). | Q27824861 | ||
| Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia | Q28204932 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7 | Q28307681 | ||
| Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification | Q33254865 | ||
| Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders | Q33374851 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts | Q34578418 | ||
| Genetics of myeloid leukemias | Q34795893 | ||
| Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. | Q35080478 | ||
| Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor | Q35080710 | ||
| Chromatin structural elements and chromosomal translocations in leukemia | Q36558869 | ||
| Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia | Q36600942 | ||
| The myeloproliferative disorders | Q36675917 | ||
| Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia | Q37007445 | ||
| Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance | Q38321981 | ||
| Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation | Q40198158 | ||
| Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations | Q40318729 | ||
| Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies | Q40639306 | ||
| Establishment and characterization of a megakaryoblast cell line with amplification of MLL. | Q41025243 | ||
| Oncogenic transcription factors in the human acute leukemias | Q41628889 | ||
| Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported i | Q43819283 | ||
| Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation | Q43824047 | ||
| Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy | Q43830946 | ||
| Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias | Q43878422 | ||
| Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. | Q43963802 | ||
| High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia | Q44654291 | ||
| Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia | Q44775999 | ||
| Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia | Q46799049 | ||
| RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. | Q50880589 | ||
| FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. | Q54008419 | ||
| Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. | Q54100578 | ||
| Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. | Q54755048 | ||
| Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia | Q57217375 | ||
| Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias | Q59511707 | ||
| Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno | Q73567637 | ||
| Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents | Q73704820 | ||
| Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors | Q74546041 | ||
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) | Q78290356 | ||
| Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia | Q78410473 | ||
| Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations | Q79850201 | ||
| A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia | Q80432945 | ||
| Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia | Q81184235 | ||
| Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML | Q81197659 | ||
| Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study | Q81258704 | ||
| RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome | Q81384522 | ||
| Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia | Q81919725 | ||
| Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases | Q82314665 | ||
| P433 | issue | 2 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 240-248 | |
| P577 | publication date | 2008-01-17 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Genetics of therapy-related myelodysplasia and acute myeloid leukemia | |
| P478 | volume | 22 |
| Q38226741 | -7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity |
| Q28389548 | A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide |
| Q38239675 | A focused review of hematopoietic neoplasms occurring in the therapy-related setting |
| Q42405743 | A long lasting puzzle for -7/7q- syndrome |
| Q34450715 | Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia |
| Q58481761 | Acute myeloid leukemia |
| Q22255602 | Advances in understanding benzene health effects and susceptibility |
| Q34400180 | Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes |
| Q38129804 | Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis |
| Q87226130 | Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome |
| Q38711833 | Benzene and childhood acute leukemia in Oklahoma |
| Q37464115 | Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc. |
| Q94521029 | Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype |
| Q53297206 | Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. |
| Q33394269 | Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH. |
| Q34734098 | Chromosome-wide aneuploidy study (CWAS) in workers exposed to an established leukemogen, benzene |
| Q35112330 | Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes |
| Q35082495 | Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities |
| Q33395996 | Clinical effect of point mutations in myelodysplastic syndromes |
| Q42586752 | Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring |
| Q39026726 | Clonal evolution in therapy-related neoplasms. |
| Q28396265 | Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment |
| Q38052129 | DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias. |
| Q51806197 | Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. |
| Q38046783 | Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. |
| Q37002149 | Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia. |
| Q42421841 | Fanconi anemia gene variants in therapy-related myeloid neoplasms. |
| Q33408270 | First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...] |
| Q37479019 | Formaldehyde induces micronuclei in mouse erythropoietic cells and suppresses the expansion of human erythroid progenitor cells |
| Q36416779 | Frequent induction of chromosomal aberrations in in vivo skin fibroblasts after allogeneic stem cell transplantation: hints to chromosomal instability after irradiation |
| Q42679067 | Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols |
| Q42195101 | Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair |
| Q37209075 | Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility |
| Q24328884 | Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7 |
| Q37585218 | Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice |
| Q43998950 | Hematologic adverse events associated with temozolomide |
| Q86030211 | High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome |
| Q85562493 | IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10) |
| Q36417421 | Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway |
| Q38893397 | Induction of centrosome amplification by formaldehyde, but not hydroquinone, in human lymphoblastoid TK6 cells |
| Q35562821 | Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia |
| Q39169829 | Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model |
| Q46441674 | Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance |
| Q39023406 | Knockdown of Hnrnpa0, a del(5q) gene, alters myeloid cell fate in murine cells through regulation of AU-rich transcripts |
| Q48028205 | Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations. |
| Q37676681 | Molecular biology of therapy-related leukaemias |
| Q35560260 | Molecular pathogenesis of secondary acute promyelocytic leukemia |
| Q36892587 | Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia |
| Q41299821 | Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases |
| Q86194930 | Myelodysplasia: new approaches |
| Q42493977 | Myelodysplastic Syndrome Occurring in a Patient with Gorlin Syndrome |
| Q36266642 | Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges |
| Q35079660 | Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor |
| Q34065032 | NF1 inactivation in adult acute myelogenous leukemia |
| Q44257677 | NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features |
| Q28384370 | Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells |
| Q26863329 | PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML |
| Q60907615 | Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms |
| Q36589635 | Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials |
| Q39808782 | Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q33755957 | Systems biology of human benzene exposure |
| Q57734311 | TET2 mutations in myelodysplasia and myeloid malignancies |
| Q35606212 | TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases |
| Q39555179 | TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes |
| Q33855938 | Taking a Bad Turn: Compromised DNA Damage Response in Leukemia |
| Q46082519 | Telomere shortening and chromosomal instability in myelodysplastic syndromes |
| Q83500609 | The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies |
| Q33717681 | The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. |
| Q37727786 | The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment |
| Q35892130 | The co-presence of deletion 7q, 20q and inversion 16 in therapy-related acute myeloid leukemia developed secondary to treatment of breast cancer with cyclophosphamide, doxorubicin, and radiotherapy: a case report |
| Q39813450 | The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status |
| Q38132064 | The evolving landscape in the therapy of acute myeloid leukemia |
| Q64109041 | The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution |
| Q36927012 | The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair |
| Q29614630 | The origin and evolution of mutations in acute myeloid leukemia |
| Q38353167 | Therapy-related myelodysplastic syndrome |
| Q37621638 | Therapy-related myelodysplastic syndrome: models and genetics |
| Q50694074 | Therapy-related myeloid neoplasm in a patient with TP53 mutation: a dilemma in allogeneic stem cell transplant. |
| Q24289420 | Toxicogenomic profiling of chemically exposed humans in risk assessment |
| Q37865545 | Unfavorable-risk cytogenetics in acute myeloid leukemia |
| Q37671806 | Unraveling the molecular pathophysiology of myelodysplastic syndromes |
| Q36126146 | Using bioinformatic approaches to identify pathways targeted by human leukemogens |
| Q33695954 | p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). |
Search more.